Eva Sahakian

2.5k total citations
66 papers, 1.7k citations indexed

About

Eva Sahakian is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Eva Sahakian has authored 66 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 20 papers in Genetics and 20 papers in Oncology. Recurrent topics in Eva Sahakian's work include Histone Deacetylase Inhibitors Research (33 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Protein Degradation and Inhibitors (16 papers). Eva Sahakian is often cited by papers focused on Histone Deacetylase Inhibitors Research (33 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Protein Degradation and Inhibitors (16 papers). Eva Sahakian collaborates with scholars based in United States, China and Czechia. Eva Sahakian's co-authors include Karrune Woan, Danielle L. Gilvary, Julie Y. Djeu, Wei Sheng, Javier Pinilla‐Ibarz, Krithika N. Kodumudi, Alejandro Villagra, John J. Powers, Eduardo M. Sotomayor and Michelle M. Lilly and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eva Sahakian

62 papers receiving 1.7k citations

Peers

Countries citing papers authored by Eva Sahakian

Since Specialization

Citations

This map shows the geographic impact of Eva Sahakian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Sahakian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Sahakian more than expected).

Fields of papers citing papers by Eva Sahakian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Sahakian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Sahakian. The network helps show where Eva Sahakian may publish in the future.

Co-authorship network of co-authors of Eva Sahakian

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Sahakian. A scholar is included among the top collaborators of Eva Sahakian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Sahakian. Eva Sahakian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL 2025 ·Blood Advances ·(unknown), (unknown), (unknown), Melanie Mediavilla-Varela, (unknown), (unknown), John J. Powers, Julio C. Chávez, Erika A. Eksioglu, Sandra Sernbo, Florencia Palacios, (unknown), (unknown), (unknown), Gimena dos Santos, (unknown), Ana Inés Landoni, Eva Sahakian, Pablo Oppezzo, Javier Pinilla‐Ibarz	1
2	Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model 2025 ·Blood Advances ·(unknown), (unknown), Helga Simon‐Molas, Melanie Mediavilla-Varela, (unknown), (unknown), (unknown), Julio C. Chávez, John J. Powers, (unknown), Timothy I. Shaw, José R. Conejo-García, Paulo C. Rodrı́guez, Eva Sahakian, Javier Pinilla‐Ibarz, Arnon P. Kater	3
3	Mycovirus-Containing Aspergillus flavus Alters Transcription Factors in Normal and Acute Lymphoblastic Leukemia Cells 2024 ·International Journal of Molecular Sciences ·Cameron K. Tebbi, (unknown), Eva Sahakian, Melanie Mediavilla-Varela, Javier Pinilla‐Ibarz, Saumil Patel, George E. Rottinghaus, (unknown), Clare Dennison	1
4	A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma 2024 ·Blood ·Hayder Saeed, (unknown), Eva Sahakian, (unknown), Qianxing Mo, Ling Zhang, (unknown), Yumeng Zhang, (unknown), (unknown), Sameh Gaballa, Julio C. Chávez, Bijal Shah, Celeste Bello, Lubomir Sokol, Javier Pinilla‐Ibarz	1
5	Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies 2022 ·Frontiers in Immunology ·(unknown), (unknown), Eva Sahakian, Javier Pinilla‐Ibarz	23
6	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention 2021 ·Blood Advances ·Lia Perez, Hugo F. Fernández, Mohamed A. Kharfan‐Dabaja, Farhad Khimani, Brian C. Betts, Asmita Mishra, Ernesto Ayala, Frederick L. Locke, (unknown), Michael L. Nieder, Joseph Pidala, (unknown), John J. Powers, Eva Sahakian, Ram Thapa, Xuefeng Wang, Claudio Anasetti	9
7	Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls 2020 ·Cancer Treatment and Research Communications ·Cameron K. Tebbi, (unknown), Eva Sahakian, John J. Powers, (unknown), Saumil Patel, (unknown)	10
8	Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavus 2020 ·Journal of Pediatric Hematology/Oncology ·Cameron K. Tebbi, (unknown), Eva Sahakian, (unknown), (unknown), John J. Powers, (unknown), Michael Jaglal, Saumil Patel, (unknown)	6
9	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells 2019 ·Scientific Reports ·Tessa Knox, Eva Sahakian, Debarati Banik, Melissa Hadley, Erica Palmer, Satish Noonepalle, Jennifer Kim, John J. Powers, Maria Gracia-Hernandez, Vasco Oliveira, Fengdong Cheng, Jie Chen, Cyril Bařinka, Javier Pinilla‐Ibarz, Norman H. Lee, Alan P. Kozikowski, Alejandro Villagra	135
10	A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function 2019 ·Blood ·Julio C. Chávez, Ariel Grajales‐Cruz, (unknown), (unknown), (unknown), Eva Sahakian, (unknown), (unknown)	3
11	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease 2018 ·Bone Marrow Transplantation ·Lia Perez, Hugo F. Fernández, Pedro Horna, Marcie Riches, Frederick L. Locke, Teresa Field, John J. Powers, Eva Sahakian, Alejandro Villagra, Asmita Mishra, Brian C. Betts, Mohamed A. Kharfan‐Dabaja, Francisca Beato, (unknown), Joseph Pidala, Claudio Anasetti	8
12	HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma 2017 ·Blood ·Jason Brayer, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Tuan Nguyen, Melissa Alsina, Taiga Nishihori, Rachid Baz, Javier Pinilla‐Ibarz, Eduardo M. Sotomayor, (unknown)	1
13	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies 2016 ·Methods in molecular biology ·John J. Powers, Maritza Lienlaf, Patricio Perez-Villarroel, Susan Deng, Tessa Knox, Alejandro Villagra, Eva Sahakian	6
14	Essential role of HDAC6 in the regulation of PD‐L1 in melanoma 2016 ·Molecular Oncology ·Maritza Lienlaf, Patricio Perez-Villarroel, Tessa Knox, Mibel Pabon, Eva Sahakian, John J. Powers, Karrune Woan, C. Lee, Fengdong Cheng, Susan Deng, Keiran S.M. Smalley, Martı́n Montecino, Alan P. Kozikowski, Javier Pinilla‐Ibarz, Amod A. Sarnaik, Edward Seto, Jeffrey S. Weber, Eduardo M. Sotomayor, Alejandro Villagra	136
15	Preparation and Biochemical Analysis of Classical Histone Deacetylases 2016 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Alejandro Villagra, Eva Sahakian, Edward Seto	1
16	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function 2014 ·Molecular Immunology ·Eva Sahakian, John J. Powers, Jie Chen, Susan Deng, Fengdong Cheng, Allison Distler, David Woods, Jennifer Rock-Klotz, Andressa L. Sodré, Je-In Youn, Karrune Woan, Alejandro Villagra, Dmitry I. Gabrilovich, Eduardo M. Sotomayor, Javier Pinilla‐Ibarz	96
17	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity 2012 ·Cancer Research ·Fengdong Cheng, Hongwei Wang, Pedro Horna, Zi Wang, Bijal Shah, Eva Sahakian, Karrune Woan, Alejandro Villagra, Javier Pinilla‐Ibarz, Saı̈d M. Sebti, Mitchell R. Smith, Jianguo Tao, Eduardo M. Sotomayor	15
18	Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75 2009 ·Molecular Cancer ·Melanie Mediavilla-Varela, Fabio J. Pacheco, Frankis Almaguel, (unknown), Eva Sahakian, Tracy R. Daniels‐Wells, Lai Sum Leoh, Amelia Padilla, Nathan R. Wall, Michelle M. Lilly, Marino De León, Carlos A. Casiano	101
19	The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells 2008 ·Journal of Biological Chemistry ·Marina Zemskova, Eva Sahakian, (unknown), Michelle M. Lilly	110
20	Ikaros Isoform X Is Selectively Expressed in Myeloid Differentiation 2003 ·The Journal of Immunology ·Kimberly J. Payne, Grace C. Huang, Eva Sahakian, Judy Zhu, Natasha S. Barteneva, Lora W. Barsky, Marvin A. Payne, Gay M. Crooks	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact